C4 Therapeutics is a biopharmaceutical company that develops therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, targeting multiple myeloma and non-Hodgkin lymphomas. The company is also developing other orally bioavailable degraders for various cancers and has collaborations with F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Calico Life Sciences LLC. C4 Therapeutics was founded in 2015 and is based in Watertown, Massachusetts.